©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Activation of p70 S6 Kinase and erk-encoded Mitogen-activated Protein Kinases Is Resistant to High Cyclic Nucleotide Levels in Swiss 3T3 Fibroblasts (*)

(Received for publication, June 30, 1995; and in revised form, August 29, 1995)

Claudia Petritsch Rüdiger Woscholski (1) Helga M. L. Edelmann Lisa M. Ballou (§)

From the Institute of Molecular Pathology, Vienna, Austria and the Imperial Cancer Research Fund, Lincoln's Inn Fields, London, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Treatment of Swiss mouse 3T3 fibroblasts with certain cyclic nucleotide phosphodiesterase inhibitors (theophylline, SQ 20,006, and MY-5445) prevents the activation of the M(r) 70,000 S6 kinase (p70) induced by a variety of external stimuli. Concentrations giving half-maximal inhibition were 800, 50, and 25 µM, respectively. Western blot analysis and immunocomplex kinase assays showed that these compounds inhibit the phosphorylation and activation of p70 without affecting the erk-encoded mitogen-activated protein (MAP) kinases or the rsk-encoded S6 kinase (p90). A distinct collection of cAMP and cGMP agonists and analogues did not suppress p70 activation, indicating that 1) high intracellular cyclic nucleotide concentrations do not antagonize the p70 pathway and 2) phosphodiesterase inhibitors block p70 activation by a mechanism that is independent of cAMP or cGMP production. The effect of theophylline and SQ 20,006, but not MY-5445, on p70 signaling may be due in part to the inhibition of a phosphatidylinositol 3-kinase that acts upstream of p70. Finally, in contrast to many other cell types, cAMP and cGMP were also found to have no inhibitory effect on the MAP kinase/p90 signaling pathway in Swiss 3T3 fibroblasts.


INTRODUCTION

Addition of mitogens to quiescent mammalian cells induces a signaling cascade that leads to the multiple phosphorylation of 40 S ribosomal protein S6(1) . S6 phosphorylation is thought to increase the rate of synthesis of certain proteins which are required for efficient G(1) progression and whose mRNAs contain a polypyrimidine tract at the 5` end(2) . Two families of mitogen-stimulated S6 kinases have been identified: the M(r) 70,000 S6 kinases (p70) (^1)(1, 3, 4) and the M(r) 90,000 ribosomal S6 kinase (p90)(5) . Enzymes in both families are activated by phosphorylation of serine/threonine residues(6, 7, 8) . p90 is activated by mitogen-activated protein (MAP) kinases (9) and participates in a signaling network that includes ras, raf-1, and Mek1(10) . By contrast, p70 lies on a distinct pathway that does not appear to include MAP kinases (11) .

Injection of antibodies that neutralize p70 activity (12) and use of the immunosuppressant rapamycin, which blocks the activation of the enzyme(13, 14) , has suggested that p70 function during the G(1) phase of the cell cycle is important for proliferation in some cell types. Three serines and one threonine clustered at the carboxyl terminus of p70 become phosphorylated in response to mitogen treatment(15) . However, recent data have shown that deletion of the carboxyl terminus (16) or mutation of the four mitogen-induced phosphorylation sites to acidic residues (^2)yields p70 molecules which can still be activated by mitogens. Therefore, the contribution of these sites to enzyme activation remains unclear. In addition to the four mitogen-responsive phosphorylation sites, p70 contains other phosphates that turn over very slowly and that appear to be essential for enzyme activity. Rapamycin induces the dephosphorylation of these unmapped sites and therefore prevents the activation of p70(17) .

Little is known about the signaling components that function upstream of p70. One approach to identify participants in the p70 pathway has been to study the mechanism of action of inhibitors of the pathway. For example, Kunz and co-workers (18) showed that rapamycin suppresses the growth of Saccharomyces cerevisiae by interacting with two gene products encoded by TOR1 and TOR2. Homologous proteins were subsequently found in higher eucaryotes(19) . These proteins show significant homology to the catalytic subunit of mammalian phosphatidylinositol (PtdIns) 3-kinase(20) , which plays an important role in mitogenesis and other cellular responses(21, 22) . It was subsequently shown that wortmannin and other specific inhibitors of mammalian PtdIns 3-kinase also prevent p70 activation induced by a variety of agents(23, 24, 25) . Together, these results suggested that PtdIns 3-kinase or a related enzyme might be involved in the activation of p70. This conclusion is supported by the recent observation that expression of a constitutively active PtdIns 3-kinase leads to activation of p70 and phosphorylation of a novel site within the kinase catalytic domain(26) .

A second possible class of inhibitors of the p70 pathway was suggested by work of Thomas and co-workers(27) , who showed that pretreatment of Swiss mouse 3T3 fibroblasts with theophylline or SQ 20,006 blocked the serum-induced phosphorylation of S6. We demonstrate here that these two compounds block S6 phosphorylation by selectively inhibiting the activation of p70. Theophylline and SQ 20,006 are best known as nonspecific cyclic nucleotide phosphodiesterase inhibitors(28, 29) that might raise the intracellular concentration of cAMP and cGMP, leading to the activation of cAMP- and cGMP-dependent protein kinases (PKA and PKG, respectively). It has recently been shown that cAMP antagonizes p70 activation in T cells (30) and the MAP kinase/p90 pathway in a number of other cell types(31, 32, 33, 34, 35) . However, we show that inhibition of p70 activation in Swiss 3T3 fibroblasts by theophylline and SQ 20,006 is independent of increased cyclic nucleotide concentrations or PKA activation. Finally, we find that cyclic nucleotides do not negatively regulate either the p70 or the MAP kinase/p90 pathways in this cell type.


EXPERIMENTAL PROCEDURES

Materials

Mouse epidermal growth factor (EGF) was purchased from Biomedical Technologies, Inc. and recombinant human platelet-derived growth factor (PDGF) was purchased from Boehringer Mannheim. Theophylline and prostaglandin E(1) (PGE(1)) were from Serva. SQ 20,006 was a gift from Bristol-Myers Squibb. Bombesin, 3-isobutyl-1-methylxanthine (IBMX), cycloheximide, phorbol 12-myristate 13-acetate (PMA), Kemptide, 8-Br-cAMP, myelin basic protein, and PKA inhibitor peptide (PKI) were from Sigma. Bovine insulin and A23187 were from Calbiochem. S(p)-8-Bromoadenosine-3`:5`-cyclic monophosphorothioate (S(p)-8-Br-cAMPS), 8-Br-cGMP, S-nitroso-N-acetylpenicillamine (SNAP), and MY-5445 were from Biolog. [-P]ATP (3000 Ci/mmol) was from Amersham Corp. Polyclonal antibodies to p90 and the M(r) 42,000 and 44,000 MAP kinases (p42 and p44) were from Upstate Biotechnology, Inc. 40 S ribosomal subunits were purified from rat liver(36) . Tissue culture medium and fetal calf serum were purchased from Life Technologies, Inc.

Cell Cultures and Extraction

Swiss mouse 3T3 fibroblasts were maintained as described previously(6) . Unless otherwise stated, all experiments were done on quiescent, contact-inhibited cells. To make extracts, the cell layers were washed twice with cold extraction buffer (20 mM Tris, 20 mM EGTA, 15 mM MgCl(2), 40 mM 4-nitrophenyl phosphate (pNPP), 1 mM dithiothreitol (DTT), and 0.1 mM phenylmethylsulfonyl fluoride (PMSF), pH 7.5), the cells were scraped into 400 µl (10-cm plates) or 180 µl (6-cm plates) of extraction buffer, and extracts were centrifuged at 8000 times g for 15 min at 4 °C. Supernatants were retained. Protein concentration was determined by a Lowry assay(37) .

Wild-type S49 mouse lymphoma cells (subclone 24.3.2) were grown as described previously(38) . To make extracts, 1-2 times 10^7 cells were centrifuged at 500 times g for 5 min, washed twice with cold phosphate-buffered saline (PBS; 137 mM NaCl, 3 mM KCl and 12 mM P(i), pH 7.4), and resuspended in 400 µl of extraction buffer. The cells were homogenized with 10 strokes in a Potter-Elvehjem homogenizer, and the homogenates were centrifuged at 4 °C. Supernatants were retained.

BAC-1 macrophages were grown to confluence in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and colony-stimulating factor-1. Cells were starved for colony-stimulating factor-1 for 27 h before use. Cells extract supernatants were prepared as described above for the fibroblasts.

S6 Kinase and MAP Kinase Assays

Extract supernatants were diluted 1:21 in S6 kinase assay buffer (50 mM Tris, 0.1 mM EGTA, 5% ethylene glycol, 5 mM DTT, 10 mM MgCl(2), 0.1% Triton X-100, and 0.25 mg/ml bovine serum albumin (BSA), pH 7.5) and assayed for S6 kinase activity as described previously(6) , except reactions also contained 2 µM PKI. One unit is the amount of enzyme that incorporates 1 pmol of P(i) into S6 per min.

For S6 kinase immunocomplex assays, extract supernatants were diluted into immunoprecipitation buffer (50 mM Tris, 1% Triton X-100, 50 mM NaCl, 20 mM NaF, 1 mM benzamidine, 5 mM EGTA, 10 mM PP(i), 30 mM pNPP, 200 µM vanadate, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 0.1% BSA, 0.1 mM DTT, and 0.1 mM PMSF, pH 7.2) and the solutions were incubated with antibodies to p70 for 2 h at 4 °C. Protein A-agarose beads (Sigma) which had been preincubated with immunoprecipitation buffer were added, and the samples were incubated for 1 h at 4 °C. The beads were washed twice with immunoprecipitation buffer and twice with S6 kinase assay buffer without DTT. S6 kinase assays were then performed as described above.

For MAP kinase immunocomplex assays, extract supernatants in immunoprecipitation buffer were incubated with antibody 122 against p42 as described above. After washing with immunoprecipitation buffer, the protein A-agarose beads were washed twice with MAP kinase assay buffer (30 mM Tris, pH 8, 20 mM MgCl(2), 2 mM MnCl(2), 0.1% Triton X-100, and 0.1 mM DTT). MAP kinase assays were initiated by adding 15 µl of MAP kinase assay buffer containing 10 µM ATP, 2 µM PKI, 10 µg of myelin basic protein, and 0.33 µl of [P]ATP. After 30 min at 37 °C the reactions were stopped by adding 10 µl of SDS sample buffer and heating at 95 °C. The reactions were subjected to electrophoresis on SDS-20% polyacrylamide gels and autoradiography.

PKA Assay

Cells were washed twice with cold PBS and homogenized with 20 strokes in 500 µl of buffer containing 10 mM potassium phosphate, 100 mM KCl, 20 mM NaF, 0.5 mM theophylline, and 0.1 mM PMSF, pH 6.8. Homogenates were centrifuged at 4 °C for 10 min at 8000 times g, and supernatants were diluted 1:21 in PKA assay buffer (S6 kinase assay buffer plus 50 mM P(i), pH 7). Protein kinase activity was determined in the presence or absence of 10 µM 8-Br-cAMP or 4 µM PKI. Diluted cell extract (10 µl) was added to 10 µl PKA assay buffer containing 100 µM ATP, 20 mM pNPP, 50 µM Kemptide and 0.1 µl [-P]ATP. Following incubation for 10 min at 30 °C, the reactions were stopped by addition of 10 µl of 10 mg/ml BSA and 10 µl of 7% trichloroacetic acid. After centrifugation the supernatants were pipetted onto Whatman P-81 paper. The papers were washed four times with cold 75 mM phosphoric acid, rinsed with ethanol, dried, and counted in a scintillation counter. PKA activity ratios were calculated as described previously(39) .

cAMP Assay

Cells were washed twice with cold PBS and lysed in 0.1 M HCl for 30 min, and the lysates were centrifuged at 4 °C for 10 min at 8000 times g. cAMP was purified from the supernatants and radioimmunoassays were performed as described in the instruction manual of the RIANEN cAMP RIA Kit.

Polyclonal Antibodies to p70

A cDNA fragment encoding amino acids 258-469 of rat p70(3) was inserted into the BamHI and HindIII sites of the vector pETH-2a (40) and expressed in Escherichia coli. The recombinant protein, which contained 12 additional amino acids at its amino terminus including 6 histidines and 2 additional amino acids at the carboxyl terminus, was purified on Ni-nitrilotriacetic acid-agarose (Quiagen) under denaturing conditions(41) . The protein was further purified on SDS-polyacrylamide gels and used to raise antisera in rabbits. Purified recombinant protein was also coupled to CNBr-activated Sepharose 4B (Pharmacia) and used to affinity purify the antibodies(42) . The purified antibodies showed no cross-reaction with p90 on Western blots or in immunocomplex kinase assays. (^3)

Immunoblots

Proteins (8 µg) in extract supernatants were resolved on SDS-15% polyacrylamide gels and electrophoretically transferred onto nitrocellulose. Membranes were blocked in 3% BSA for 1 h and incubated for 2-15 h in PBS, 0.5% Tween 20 containing purified antibody to p70 (1:1000 dilution), MAP kinase R2 antibody (recognizes p42 and p44; 1:1000), or p90 antibody (1:1000). Membranes were washed several times and further incubated with anti-rabbit horseradish peroxidase-linked whole antibodies from donkey (1:5000; Amersham Corp.) for 1 h. Specific signals were detected with the ECL kit (Amersham).

PtdIns 3-kinase Assays

The catalytic (p110alpha) and regulatory (p85beta) subunits of PtdIns 3-kinase were expressed in insect cells using the baculovirus system and partially purified by ion exchange and heparin chromatography(43) . Lipid kinase assays were performed using PtdIns 4,5-bisphosphate as substrate as described elsewhere(43) .

Anion Exchange Chromatography

Cells treated as described in the text were washed twice with cold buffer A (25 mM Tris, 40 mM pNPP, 2 mM EGTA, 1 mM DTT, and 1 mM benzamidine, pH 7.5) containing 0.1 mM PMSF, scraped into 900 µl/plate of buffer A containing PMSF and 0.1% Triton X-100 and homogenized with five strokes in a Potter-Elvehjem homogenizer. The homogenate was centrifuged at 4 °C for 10 min at 8000 times g, and the supernatant was applied to a 0.5-ml Mono Q column (Pharmacia Biotech Inc.) at a flow rate of 0.5 ml/min. After the column was washed with 2 ml of buffer A plus 0.1% Triton X-100, bound material was eluted with a 10-ml linear gradient from 0 to 0.5 M NaCl in buffer A plus 0.1% Triton X-100. Fractions (0.5 ml) were collected and assayed for S6 kinase activity.


RESULTS

Inhibition of S6 Kinase Activation by Theophylline and SQ 20,006

It was shown earlier that high concentrations of the nonspecific phosphodiesterase inhibitors theophylline and SQ 20,006 block the serum-induced phosphorylation of S6 in intact fibroblasts (27) . This effect could be mediated by inhibition of an S6 kinase or activation of an S6 phosphatase. To test the first possibility, quiescent fibroblasts were pretreated with or without theophylline or SQ 20,006, and then EGF was added to stimulate S6 kinase. In control cells S6 kinase was maximally activated after 10 min of EGF treatment and then the activity slowly decreased (Fig. 1A). Pretreatment with theophylline or SQ 20,006 lowered the basal level of S6 kinase activity in unstimulated cells and greatly reduced the EGF-induced activation of the enzyme (Fig. 1A). Similar results were obtained with 2 mM IBMX, another nonspecific phosphodiesterase inhibitor that is structurally related to theophylline.^3 Dose-response curves showed that the concentrations of theophylline and SQ 20,006 that inhibit S6 kinase activation 50% (IC) were 800 µM and 50 µM, respectively (Fig. 2). Thus, theophylline and SQ 20,006 block S6 phosphorylation in vivo by causing the inhibition of an S6 kinase.


Figure 1: Effect of cyclic nucleotide reagents on the EGF-induced activation of S6 kinase. Fibroblasts were pretreated as described below and then at t = 0 min 5 nM EGF was added for the indicated times. Extract supernatants were prepared and assayed for S6 kinase activity as described under ``Experimental Procedures.'' Results are means of at least two independent experiments. A, fibroblasts were pretreated with 5 mM theophylline (circle), 1 mM SQ 20,006 (box) or without drug () for 15 min. B, fibroblasts were untreated () or pretreated with 300 µM PGE(1) for 15 min (box) or with 500 µM 8-Br-cAMP (up triangle) or 500 µMS(p)-8-Br-cAMPS (circle) for 30 min. C, fibroblasts were untreated (), or pretreated with 500 µM 8-Br-cGMP (circle) for 30 min or with 300 µM MY-5445 () or 300 µM SNAP (up triangle) for 15 min.




Figure 2: Dose response for inhibition of S6 kinase activation. Fibroblasts were pretreated for 15 min with increasing concentrations of theophylline (bullet), SQ 20,006 (box) or MY-5445 () and then stimulated for 20 min with 5 nM EGF. S6 kinase activity was measured in cell extract supernatants. Results show averages of at least two determinations.



Selective Inhibition of p70 Activation by Theophylline and SQ 20,006

Mouse fibroblasts contain both p90 and p70(44) . The majority of S6 kinase activity measured in cell extracts using 40 S ribosomal subunits as a substrate is contributed by p70. To determine which of these kinases is sensitive to theophylline and SQ 20,006, p90 and p70 in fibroblast extracts were assayed after separating the two enzymes on an anion exchange column (Fig. 3A). The identity of p90 and p70 was confirmed by immunocomplex kinase assays using antibodies specific for each enzyme.^3 Untreated quiescent cells showed a low level of S6 kinase activity, all of which appeared in a peak corresponding to p70 (Fig. 3A, fraction 15). Treatment with SQ 20,006 almost completely abolished this basal activity. When control cells were exposed to EGF for a short time to maximally activate p90 (see Fig. 6C) a small peak of activity corresponding to this enzyme appeared in fraction 7; p70 was activated to a much larger extent (Fig. 3A, open circles). Pretreatment of cells with SQ 20,006 almost completely blocked the EGF-induced activation of p70 but did not inhibit p90 (Fig. 3A, closed circles). Virtually identical results were obtained with theophylline.^3 Immunocomplex kinase assays of p70 also showed that this enzyme could no longer be activated by EGF in cells pretreated with theophylline or SQ 20,006 (Fig. 3B, upper panel, lanes 1-4). Thus, the effect of SQ 20,006 and theophylline seen in extracts (Fig. 1A) is due to the selective inhibition of p70.


Figure 3: Selective inhibition of p70 activation and phosphorylation. A, separation of p70 and p90 by anion exchange chromatography. Fibroblasts (4 times 15 cm plates) were treated with PBS (), 5 nM EGF for 2.5 min (circle), 1 mM SQ 20,006 for 15 min (box), or 1 mM SQ 20,006 for 15 min followed by 5 nM EGF for 2.5 min (bullet). Cell extract supernatants were subjected to chromatography on a Mono Q column and fractions were assayed for S6 kinase activity (see ``Experimental Procedures''). B, cells were pretreated as described below and then treated without (lane 1) or with (lanes 2-9) 5 nM EGF for 20 min. p70 was then assayed in immunoprecipitates (upper panel) or subjected to Western blot analysis (lower panel) as described in ``Experimental Procedures.'' The upper panel shows an autoradiograph of P(i) incorporated into S6 during the kinase assay. Pretreatments were: lanes 1 and 2, PBS, 15 min; lane 3, 5 mM theophylline, 15 min; lane 4, 1 mM SQ 20,006, 15 min; lane 5, 500 µM 8-Br-cAMP, 30 min; lane 6, 500 µMS(p)-8-Br-cAMPS, 30 min; lane 7, 300 µM PGE(1), 15 min; lane 8, 500 µM 8-Br-cGMP, 30 min; and lane 9, 300 µM MY-5445, 15 min.




Figure 6: Effect of cyclic nucleotide reagents on MAP kinases and p90. A, fibroblasts were treated with 5 nM EGF for the indicated times and p42 and p44 were detected on Western blots. B, cells were pretreated as described below and then treated without (lane 1) or with 5 nM EGF (lanes 2-9), 1 nM insulin (lanes 10 and 11) or 384 pM PDGF (lanes 12 and 13) for 5 min. p42 in cell extract supernatants was then assayed in immunoprecipitates (upper panel) and p42 and p44 were subjected to Western blot analysis (lower panel) as described under ``Experimental Procedures.'' The upper panel shows an autoradiograph of P(i) incorporated into myelin basic protein during the kinase assay. Pretreatments were: lanes 1, 2, 10, and 12, PBS, 15 min; lane 3, 5 mM theophylline, 15 min; lane 4, 1 mM SQ 20,006, 15 min; lanes 5, 11, and 13, 500 µM 8-Br-cAMP, 30 min; lane 6, 500 µMS(p)-8-Br-cAMPS, 30 min; lane 7, 300 µM PGE(1), 15 min; lane 8, 500 µM 8-Br-cGMP, 30 min; and lane 9, 300 µM MY-5445, 15 min. C, Western blot analysis of p90. Cell treatments were the same as described above for B.



All evidence obtained so far indicates that p70 is activated by phosphorylation(7, 15, 17, 26) . Therefore, theophylline and SQ 20,006 might reduce p70 activity either by affecting its phosphorylation or by stimulating the degradation of the enzyme. To distinguish between these two possibilities, we examined the protein levels and phosphorylation state of p70 on immunoblots. p70 migrates differently in SDS-polyacrylamide gels depending on its phosphorylation state, with the highly phosphorylated and active form migrating more slowly than the dephosphorylated, inactive enzyme(7) . In resting cells the kinase was present mainly as hypophosphorylated species and kinase activity in immunoprecipitates was low (Fig. 3B, lane 1). After EGF treatment p70 activity increased and only the most highly phosphorylated forms were detected on the immunoblot (Fig. 3B, lane 2). When EGF was added to cells pretreated with theophylline or SQ 20,006 most of the p70 molecules remained hypophosphorylated and the kinase activity did not increase (Fig. 3B, lanes 3 and 4). These data demonstrate that theophylline and SQ 20,006 either prevent the EGF-induced phosphorylation of p70 or stimulate its dephosphorylation. In addition, no change in p70 protein levels was seen after treatment with theophylline or SQ 20,006 (Fig. 3B, lower panel), indicating that these agents do not induce the degradation of the enzyme.

p70 Activation Is Resistant to High Levels of cAMP and PKA Activity

Since theophylline and SQ 20,006 act as cyclic nucleotide phosphodiesterase inhibitors in vitro(28, 29) , the negative regulation of p70 by these two compounds in intact cells might be mediated by cAMP and PKA. However, cAMP and PKA did not inhibit p70 activity directly in an in vitro assay.^3 To determine whether high cAMP levels or PKA activity antagonize the p70 pathway in vivo, several specific cAMP agonists and analogues were tested for the ability to block S6 kinase activation. The compounds tested included PGE(1), a hormone that activates adenylyl cyclase through a specific receptor, and 8-Br-cAMP and S(p)-8-Br-cAMPS, which are cell-permeant, hydrolysis-resistant cAMP analogues. To our surprise, none of these compounds was an effective inhibitor of the EGF-induced activation of p70 (Fig. 1B). Immunocomplex kinase assays and Western analysis confirmed that the EGF-induced phosphorylation and activation of p70 still occurred in cells pretreated with 8-Br-cAMP, S(p)-8-Br-cAMPS or PGE(1) (Fig. 3B, lanes 5-7). PKA assays and cAMP radioimmunoassays indicated that, as expected, PGE(1), 8-Br-cAMP, and S(p)-8-Br-cAMPS activated PKA, and PGE(1) increased cAMP levels (Table 1). However, despite the known ability of theophylline and SQ 20,006 to inhibit phosphodiesterases in vitro(28, 29) , we did not detect a significant activation of PKA or an increase in cAMP levels after treatment of cells with these two compounds (Table 1).



In addition to EGF, p70 is activated by a wide variety of agonists that act by different mechanisms. These include peptide growth factors that function through receptor-tyrosine kinases (insulin and PDGF) or receptors coupled to guanosine nucleotide-binding proteins (bombesin), the Ca ionophore A23187, the protein kinase C activator PMA and cycloheximide. To determine whether 8-Br-cAMP inhibits p70 activation induced by any of these other compounds, cells were pretreated with or without 8-Br-cAMP and then exposed to one of these p70 agonists. Cell extracts were prepared at those times when p70 was maximally stimulated. Kinase activity was increased to distinct levels and pretreatment with 8-Br-cAMP had little or no effect on the activation of p70 induced by any of the compounds tested (Table 2). By contrast, theophylline strongly inhibited the activation of p70 by every agonist tested (Table 2). Three conclusions can be made from these results. First, cAMP and PKA do not antagonize the p70 activation pathway in fibroblasts. Second, theophylline and SQ 20,006 block p70 signaling by a mechanism that is independent of cAMP or PKA. And third, the target of theophylline seems to be a common regulatory element in p70 signaling pathways induced by different agonists.



Effect of cAMP on p70 Activation in Other Cell Types

In contrast to our results in fibroblasts (Fig. 3B and Table 2), cAMP has been reported to block the activation of p70 in T cells(30) . T cells are unlike Swiss fibroblasts in that they undergo growth arrest in response to high intracellular cAMP concentrations(45) . We therefore determined if an inhibitory effect of cAMP on p70 also occurs in two additional cell lines whose proliferation is sensitive to cAMP(38, 46) . Cycling wild-type S49 mouse lymphoma cells (38) exhibited a relatively high level of S6 kinase activity that was not significantly reduced in the presence of 8-Br-cAMP (Fig. 4). Similar results were obtained with cycling Swiss fibroblasts (Fig. 4). In addition, the activation of S6 kinase in BAC-1 macrophages (46) induced by colony-stimulating factor-1 was not decreased but rather augmented by 8-Br-cAMP (Fig. 4). Chromatography of cell extract supernatants on a Mono Q column (see Fig. 3A) confirmed that the major S6 kinase activity in lymphocytes and macrophages is contributed by p70.^3 Thus, p70 can be activated in the presence of high intracellular cAMP concentrations in some cell types whose proliferation is arrested by cAMP.


Figure 4: Effect of 8-Br-cAMP on p70 activity in different cell types. Cycling S49 lymphoma cells or Swiss fibroblasts were treated for 30 min with PBS (black bars) or 500 µM 8-Br-cAMP (gray bars). BAC-1 macrophages were co-treated for 15 min with 24,000 units/ml of colony-stimulating factor-1 in the presence (gray bars) or absence (black bars) of 500 µM 8-Br-cAMP. Extract supernatants were prepared and assayed for S6 kinase activity (see ``Experimental Procedures'').



Activation of p70 Is Resistant to High cGMP Levels

Theophylline and SQ 20,006 also inhibit cGMP-specific phosphodiesterases (28, 29) and by this mechanism may increase cGMP levels and activate PKG. We therefore tested specific cGMP agonists for the ability to inhibit p70 activation. MY-5445, an inhibitor of cGMP-specific phosphodiesterases, completely blocked the activation of p70 by EGF (Fig. 1C) with an IC of 25 µM (Fig. 2). By contrast, SNAP, an activator of guanylyl cyclase, and 8-Br-cGMP showed little effect on p70 activity (Fig. 1C). Therefore, no correlation between increased cGMP levels and suppression of the p70 activation pathway was evident. Immunocomplex kinase assays and Western analysis confirmed that inhibition of the EGF-induced activation of p70 by MY-5445 was not mimicked by 8-Br-cGMP (Fig. 3B, lanes 8 and 9). In addition, 8-Br-cGMP did not reduce the stimulation of p70 in response to other agonists (Table 2). These results indicate that cGMP does not negatively regulate p70.

Theophylline and SQ 20,006 Inhibit PtdIns 3-Kinase in Vitro

A variety of evidence suggests that a PtdIns 3-kinase can be involved in the activation of p70(23, 24, 25, 26) . We therefore tested whether the three inhibitors of p70 activation identified here have an effect on PtdIns 3-kinase activity in vitro. Dose-response experiments showed that theophylline and SQ 20,006 significantly inhibited lipid kinase activity in vitro, with IC values of 810 µM and 183 µM, respectively (Fig. 5). MY-5445 did not inhibit PtdIns 3-kinase activity at concentrations up to 1.25 mM (Fig. 5). Thus, one in vivo target of theophylline and SQ 20,006 might be a PtdIns 3-kinase that functions upstream of p70.


Figure 5: Dose-response for inhibition of PtdIns 3-kinase activity. Partially purified p110alphabulletp85beta heterodimers were incubated with increasing amounts of theophylline (bullet), SQ 20,006 (box) or MY-5445 () and assayed for lipid kinase activity (see ``Experimental Procedures'').



No Inhibition of MAP Kinase Activation by Cyclic Nucleotide Reagents

It has been reported that cAMP antagonizes the activation of MAP kinases in a number of different cell types(31, 32, 33, 34) . We therefore tested whether cAMP has a similar effect in Swiss fibroblasts. To determine the conditions under which MAP kinases become fully activated, a time course of kinase activation was visualized on Western blots probed with antibodies that recognize two erk-encoded MAP kinases referred to as p42 and p44. The two MAP kinases were fully activated 2.5 min after addition of EGF, as indicated by their shift to a slower mobility due to phosphorylation (Fig. 6A). The kinases remained maximally active for up to 5 min and then dephosphorylated species appeared after 10 min (Fig. 6A). Subsequent experiments were done using extracts from fibroblasts stimulated for 5 min with EGF.

To directly examine the effect of cyclic nucleotide reagents on MAP kinase activity, the erk-2-encoded p42 was precipitated with a specific polyclonal antibody and assayed in immunocomplexes. These assays showed that p42 was strongly activated by EGF (Fig. 6B, upper panel, lanes 1 and 2). This response was still fully intact in cells pretreated with cAMP analogues or PGE(1) (Fig. 6B, upper panel, lanes 5-7). p42 was also activated normally in cells pretreated with 8-Br-cGMP (Fig. 6B, upper panel, lane 8). In contrast to the results obtained with p70 ( Fig. 1and Fig. 3B), pretreatment of cells with theophylline, SQ 20,006, or MY-5445 did not block the activation of p42 by EGF (Fig. 6B, upper panel, lanes 3, 4, and 9). Thus, these compounds do not disrupt all EGF receptor-mediated responses. We also tested whether MAP kinase activation induced by insulin or PDGF is affected by cAMP. Although these two growth factors were relatively poor activators of p42 at these concentrations, it was evident that addition of 8-Br-cAMP had no inhibitory effect (Fig. 6B, upper panel, lanes 10-13). Examination of MAP kinases in these cell extracts on Western blots indicated that the activation of p44, like p42, was also resistant to high cyclic nucleotide levels and phosphodiesterase inhibitors (Fig. 6B, lower panel). In addition, the growth factor-induced mobility shift of p90 was not affected by these reagents (Fig. 6C); these results confirm and extend the finding in Fig. 3A. Thus, in Swiss 3T3 fibroblasts activation of the erk-encoded MAP kinases and p90 is not antagonized by cAMP or cGMP.


DISCUSSION

It was reported earlier that treatment of Swiss mouse 3T3 fibroblasts with the nonselective phosphodiesterase inhibitors theophylline and SQ 20,006 blocks the mitogen-induced phosphorylation of ribosomal protein S6(27) . We show here that these two compounds mediate this effect by inhibiting the activation of p70 (Fig. 3). Theophylline and SQ 20,006 did not act as general kinase inhibitors or disrupt all receptor-mediated responses, as shown by the fact that activation of MAP kinases and p90 was not inhibited (Fig. 3A and 6). Thus, like rapamycin (13, 14) and wortmannin(23, 24, 25) , theophylline and SQ 20,006 are selective inhibitors of the p70 pathway as opposed to the MAP kinase/p90 pathway. Also like rapamycin and wortmannin, theophylline and SQ 20,006 did not inhibit p70 directly^3, but rather caused a reduction in the phosphate content of the protein (Fig. 3B). This could be due to activation of a negative regulator of the p70 pathway or inhibition of a positive regulator. Inhibition by theophylline was rapidly reversed by washing out the inhibitor even in the presence of cycloheximide,^3 indicating that all of the components required for p70 activation are still present in theophylline-treated cells.

Theophylline and SQ 20,006 inhibit cyclic nucleotide phosphodiesterases in vitro(28, 29) . Therefore, one hypothesis to explain the mechanism of inhibition of p70 would be that the compounds increase intracellular cAMP levels, and as a result PKA is activated and phosphorylates a regulatory protein in the p70 pathway. However, several lines of evidence indicate that cAMP/PKA do not negatively regulate p70 in these cells. First, theophylline and SQ 20,006 were not found to be effective cAMP agonists under conditions in which p70 was inhibited (Table 1). This result is consistent with other reports that theophylline has little or no effect on basal cAMP levels in mouse fibroblasts(47) . Second, increasing the intracellular cAMP concentration by addition of cell-permeant cAMP analogues or PGE(1) did not block the stimulation of p70 induced by EGF (Fig. 1B) or other agonists (Table 2), even though PKA was strongly activated (Table 1). These results are consistent with the observation made earlier that PGE(1) does not inhibit serum-induced S6 phosphorylation in vivo(27) . Finally, work by others has shown that cAMP/PKA promotes the proliferation of Swiss mouse 3T3 fibroblasts(48) ; therefore, this pathway would not be expected to interfere with the activation of p70, which is also required for efficient cell cycle progression in this cell type(12, 13) .

In contrast to our results, Monfar et al.(30) recently reported that cAMP inhibits the interleukin-2-mediated activation of p70 in CTLL-20 T cells, in part by antagonizing the activity of PtdIns 3-kinase. This discrepancy could be due to cell type or agonist specificity. Unlike Swiss fibroblasts, T cells arrest in the G(1) phase of the cell cycle in response to high cAMP concentrations (45) or rapamycin treatment(49) . Since rapamycin inhibits interleukin-2-mediated p70 activation(14) , it seems plausible that the p70 pathway could also be the target for a cAMP-dependent cell cycle block in T cells. On the other hand, Monfar et al. (30) used forskolin/IBMX as a cAMP agonist, raising the possibility that p70 activation in CTLL-20 T cells might be sensitive to forskolin/IBMX and not to cAMP per se. Our finding that 8-Br-cAMP has no effect on p70 activity in a T cell lymphoma line (Fig. 4) also suggests that the sensitivity of T cell p70 to IBMX/forskolin might be independent of cAMP. Macrophages also arrest in the G(1) phase of the cell cycle in response to high cAMP levels or exposure to rapamycin (46) . We found that 8-Br-cAMP enhances rather than inhibits the activation of p70 by colony-stimulating factor-1 in these cells (Fig. 4).

Since theophylline and SQ 20,006 also inhibit cGMP-specific phosphodiesterases in vitro(28, 29) , we explored the possibility that cGMP and PKG might be involved in the inhibition of p70 activation. Although MY-5445, a selective inhibitor of cGMP-specific phosphodiesterases, strongly blocked the activation of p70, 8-Br-cGMP and SNAP, a guanylyl cyclase activator, had no effect (Fig. 1C and Table 2). These results strongly suggest that inhibition of p70 by MY-5445 is not a consequence of increased cGMP production or PKG activity.

Having ruled out the possibility that cAMP/PKA or cGMP play a role in theophylline-induced p70 inhibition, we searched for alternative mechanisms that might mediate this response. PtdIns 3-kinase, which has been proposed to act as a positive upstream regulator of p70(23, 24, 25, 26) , seemed to be a likely target. Indeed, we show here that theophylline and SQ 20,006, but not MY-5445, also inhibit PtdIns 3-kinase activity in vitro (Fig. 5). However, inhibition of PtdIns 3-kinase cannot be the only reason why theophylline blocks the p70 pathway. We showed earlier that wortmannin, a specific inhibitor of PtdIns 3-kinase, is a poor inhibitor of bombesin- and PMA-induced p70 activation(25) . We concluded from those studies that some pathways leading to p70 activation are independent of PtdIns 3-kinase(25) . By contrast, theophylline strongly inhibited the p70 response to all of the agonists listed in Table 2, including bombesin and PMA. These data suggest that theophylline might act on another target in addition to PtdIns 3-kinase. This target appears to be a regulatory element that functions either independently of all activation pathways (such as a p70 phosphatase) or in every pathway (such as a p70 kinase).

Theophylline has several other known cellular effects that could play a role in its ability to inhibit the activation of p70. Theophylline mobilizes intracellular Ca by opening ryanodine receptor Ca channels (50) and is a potent antagonist of adenosine receptors(29, 51) . The possible role of Ca or adenosine receptors in the activation of p70 remains to be tested. More importantly, many purine analogues and derivatives such as theophylline are competitive inhibitors of kinases due to a structural similarity to ATP (52) . This property may account for the ability of theophylline to inhibit PtdIns 3-kinase activity in vitro (Fig. 5). Therefore, theophylline may inhibit the p70 pathway by targeting an upstream kinase that is required for a response to all agonists tested so far. Since no such upstream component has been identified yet, this hypothesis cannot be tested directly. SQ 20,006 and MY-5445 bear some structural resemblance to theophylline and may act in a similar manner. Identification or design of specific and potent inhibitors of p70 activation, based on the compounds we identified here, could lead to the isolation of upstream activators that function in this pathway.

We show here that the activation of p42/p44 and p90 in Swiss fibroblasts is also resistant to high cAMP and cGMP levels (Fig. 6). MAP kinase activation in PC12 cells is similarly resistant to high cAMP levels(31) . By contrast, negative regulation of the MAP kinase/p90 cascade by cAMP has been observed in Xenopus oocytes, Rat1 cells, smooth muscle cells, CHO cells, and adipocytes stimulated with a variety of agonists(32, 33, 34, 35) . In some of these cell types high cAMP levels also antagonize cell proliferation (33, 34) or meiotic cell division(35) . Several different mechanisms may contribute to inhibition of MAP kinase activation, including a reduced activation of Raf-1 due to phosphorylation by PKA(34) .

Our results, together with those from other laboratories, indicate that cyclic nucleotide-dependent signaling may interact in a variety of ways with the p70 and MAP kinase/p90 pathways. These interactions may be important for generating cell type-specific responses to identical physiological conditions. Identification of regulatory components in the p70 pathway will allow us to further elucidate the mechanisms of cell type-specific control.


FOOTNOTES

*
This work was supported in part by a grant from the Austrian Industrial Research Promotion Fund. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Institute of Molecular Pathology, Dr. Bohr-Gasse 7, A-1030 Vienna, Austria. Tel.: 1-797-30 (ext. 841); Fax: 1-798-7153; IN%“ballou@aimp.una.ac.at”.

(^1)
The abbreviations used are: p70, M(r) 70,000 S6 kinase; MAP, mitogen-activated protein; p90, M(r) 90,000 ribosomal S6 kinase; p42/p44, M(r) 42,000 and 44,000 MAP kinases; PtdIns, phosphatidylinositol; PBS, phosphate-buffered saline; EGF, epidermal growth factor; PDGF, platelet-derived growth factor; PGE(1), prostaglandin E(1); IBMX, 3-isobutyl-1-methylxanthine; PMA, phorbol 12-myristate 13-acetate; PKA, cAMP-dependent protein kinase; PKG, cGMP-dependent protein kinase; PKI, PKA inhibitor peptide; S(p)-8-Br-cAMPS, S(p)-8-bromoadenosine-3`:5`-cyclic monophosphorothioate; pNPP, 4-nitrophenyl phosphate; DTT, dithiothreitol; PMSF, phenylmethylsulfonyl fluoride; SNAP, S-nitroso-N-acetylpenicillamine; IC, concentration giving 50% inhibition; BSA, bovine serum albumin.

(^2)
H. M. L. Edelmann, C. Kühne, C. Petritsch, and L. M. Ballou, manuscript submitted for publication.

(^3)
C. Petritsch, H. M. L. Edelmann, and L. M. Ballou, unpublished observations.


ACKNOWLEDGEMENTS

We thank G. Thomas for the p70 cDNA, M. Busslinger for pETH-2a, R. A. Steinberg for the lymphoma cells, C. Marshall for the p42 antibody and M. Baccarini for the BAC-1 cells. We also thank G. Christofori, M. Baccarini, W. Ellmeier, and P. J. Parker for helpful comments and H. Tkadletz for help with the figures.


REFERENCES

  1. Ferrari, S., and Thomas, G. (1994) Crit. Rev. Biochem. Mol. Biol. 29, 385-413 [Abstract]
  2. Jefferies, H. B. J., Reinhard, C., Kozma, S. C., and Thomas, G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4441-4445 [Abstract]
  3. Kozma, S. C., Ferrari, S., Bassand, P., Siegmann, M., Totty, N., and Thomas, G. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7365-7369 [Abstract]
  4. Banerjee, P., Ahmad, M. F., Grove, J. R., Kozlosky, C., Price, D. J., and Avruch, J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8550-8554 [Abstract]
  5. Jones, S. W., Erikson, E., Blenis, J., Maller, J. L., and Erikson, R. L. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 3377-3381 [Abstract]
  6. Ballou, L. M., Jenö, P., and Thomas, G. (1988) J. Biol. Chem. 263, 1188-1194 [Abstract/Free Full Text]
  7. Ballou, L. M., Siegmann, M., and Thomas, G. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7154-7158 [Abstract]
  8. Erikson, E., and Maller, J. L. (1989) J. Biol. Chem. 264, 13711-13717 [Abstract/Free Full Text]
  9. Sturgill, T. W., Ray, L. B., Erikson, E., and Maller, J. L. (1988) Nature 334, 715-718 [CrossRef][Medline] [Order article via Infotrieve]
  10. Marshall, C. J. (1994) Curr. Topics Genet. Dev. 4, 82-89
  11. Ballou, L. M., Luther, H., and Thomas, G. (1991) Nature 349, 348-350 [CrossRef][Medline] [Order article via Infotrieve]
  12. Lane, H. A., Fernandez, A., Lamb, N. J. C., and Thomas, G. (1993) Nature 363, 170-172 [CrossRef][Medline] [Order article via Infotrieve]
  13. Chung, J., Kuo, C. J., Crabtree, G. R., and Blenis, J. (1992) Cell 69, 1227-1236 [Medline] [Order article via Infotrieve]
  14. Kuo, C. J., Chung, J., Fiorentino, D. F., Flanagan, W. M., Blenis, J., and Crabtree, G. R. (1992) Nature 358, 70-73 [CrossRef][Medline] [Order article via Infotrieve]
  15. Ferrari, S., Bannwarth, W., Morley, S. J., Totty, N. F., and Thomas, G. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7282-7286 [Abstract]
  16. Weng, Q.-P., Andrabi, K., Kozlowski, M. T., Grove, J. R., and Avruch, J. (1995) Mol. Cell. Biol. 15, 2333-2340 [Abstract]
  17. Ferrari, S., Pearson, R. B., Siegmann, M., Kozma, S., and Thomas, G. (1993) J. Biol. Chem. 268, 16091-16094 [Abstract/Free Full Text]
  18. Kunz, J., Henriquez, R., Schneider, U., Deuter-Reinhard, M., Movva, N. R., and Hall, M. N. (1993) Cell 73, 585-596 [Medline] [Order article via Infotrieve]
  19. Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C. T., Lane, W. S., and Schreiber, S. L. (1994) Nature 369, 756-758 [CrossRef][Medline] [Order article via Infotrieve]
  20. Hiles, I. D., Otsu, M., Volinia, S., Fry, M. J., Gout, I., Dhand, R., Panayotou, G., Ruiz-Larrea, F., Thompson, A., Totty, N. F., Hsuan, J. J., Courtneidge, S. A., Parker, P. J., and Waterfield, M. D. (1992) Cell 70, 419-429 [Medline] [Order article via Infotrieve]
  21. Parker, P. J., and Waterfield, M. D. (1992) Cell Growth & Differ. 3, 747-752
  22. Varticovski, L., Harrison-Findik, D., Keeler, M. L., and Susa, M. (1994) Biochim. Biophys. Acta 1226, 1-11 [Medline] [Order article via Infotrieve]
  23. Cheatham, B., Vlahos, C. J., Cheatham, L., Wang, L., Blenis, J., and Kahn, C. R. (1994) Mol. Cell. Biol. 14, 4902-4911 [Abstract]
  24. Chung, J., Grammer, T. C., Lemon, K. P., Kazlauskas, A., and Blenis, J. (1994) Nature 370, 71-75 [CrossRef][Medline] [Order article via Infotrieve]
  25. Petritsch, C., Woscholski, R., Edelmann, H. M. L., Parker, P. J., and Ballou, L. M. (1995) Eur. J. Biochem. 230, 431-438 [Abstract]
  26. Weng, Q.-P., Andrabi, K., Klippel, A., Kozlowski, M. T., Williams, L. T., and Avruch, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5744-5748 [Abstract]
  27. Thomas, G., Siegmann, M., Kubler, A.-M., Gordon, J., and Jimenez de Asua, L. (1980) Cell 19, 1015-1023 [Medline] [Order article via Infotrieve]
  28. Chasin, M., Harris, D. N., Phillips, M. B., and Hess, S. M. (1972) Biochem. Pharmacol. 21, 2443-2450 [CrossRef][Medline] [Order article via Infotrieve]
  29. Beavo, J. A., and Reifsnyder, D. H. (1990) Trends Pharmacol. Sci. 11, 150-155 [CrossRef][Medline] [Order article via Infotrieve]
  30. Monfar, M., Lemon, K. P., Grammer, T. C., Cheatham, L., Chung J., Vlahos, C. J., and Blenis, J. (1995) Mol. Cell. Biol. 15, 326-337 [Abstract]
  31. Burgering, B. M. T., Pronk, G. J., van Weeren, P. C., Chardin, P., and Bos, J. L. (1993) EMBO J. 12, 4211-4220 [Abstract]
  32. Sevetson, B. R., Kong, X., and Lawrence, J. C. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10305-10309 [Abstract]
  33. Graves, L. M., Bornfeldt, K. E., Raines, E. W., Potts, B. C., Macdonald, S. G., Ross, R., and Krebs, E. G. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10300-10304 [Abstract]
  34. Wu, J., Dent, P., Jelinek, T., Wolfman, A., Weber, M. J., and Sturgill, T. W. (1993) Science 262, 1065-1069 [Medline] [Order article via Infotrieve]
  35. Sadler, S. E. (1991) Mol. Endocrinol. 5, 1947-1954 [Abstract]
  36. Krieg, J., Olivier, A. R., and Thomas, G. (1988) Methods Enzymol. 164, 575-581 [Medline] [Order article via Infotrieve]
  37. Peterson, G. L. (1983) Methods Enzymol. 91, 95-119 [Medline] [Order article via Infotrieve]
  38. Steinberg, R. A., van Daalen Wetters, T., and Coffino, P. (1978) Cell 15, 1351-1361 [Medline] [Order article via Infotrieve]
  39. Rothermel, J. D., Jastorff, B., and Botelho, L. H. P. (1984) J. Biol. Chem. 259, 8151-8155 [Abstract/Free Full Text]
  40. Adams, B., Doerfler, P., Aguzzi, A., Kozmik, Z., Urbanek, P., Maurer-Fogy, I., and Busslinger, M. (1992) Genes & Dev. 6, 1589-1607
  41. Hochuli, E., Bannwarth, W., Doebeli, H., Gentz, R., and Stueber, D. (1988) Bio/Technology 6, 1321-1325
  42. Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual , pp. 511-552, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  43. Woscholski, R., Dhand, R., Fry, M. J., Waterfield, M. D., and Parker, P. J. (1994) J. Biol. Chem. 269, 25067-25072 [Abstract/Free Full Text]
  44. Chen, R.-H., Chung, J., and Blenis, J. (1991) Mol. Cell. Biol. 11, 1861-1867 [Medline] [Order article via Infotrieve]
  45. Johnson, K. W., Davis, B. H., and Smith, K. A. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 6072-6076 [Abstract]
  46. Kato, J., Matsuoka, M., Polyak, K., Massague, J., and Sherr, C. J. (1994) Cell 79, 487-496 [Medline] [Order article via Infotrieve]
  47. Maganiello, V., and Vaughan, M. (1972) Proc. Natl. Acad. Sci. U. S. A. 69, 269-273 [Abstract]
  48. Rozengurt, E. (1986) Science 234, 161-166 [Medline] [Order article via Infotrieve]
  49. Dumont, F. J., Staruch, M. J., Koprak, S. L., Melino, M. R., and Sigal, N. H. (1990) J. Immunol. 144, 251-258 [Abstract/Free Full Text]
  50. Berridge, M. J. (1993) Nature 361, 315-325 [CrossRef][Medline] [Order article via Infotrieve]
  51. Fredholm, B. B., and Persson, C. G. A. (1982) Eur. J. Pharmacol. 81, 673-676 [CrossRef][Medline] [Order article via Infotrieve]
  52. Vesely, J., Havlicek, L., Strnad, M., Blow, J. J., Donella-Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., and Meijer, L. (1994) Eur. J. Biochem. 224, 771-786 [Abstract]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.